Speaker(s): 

Allison Cebulko, RPh, PharmD, BCCP, Staff Member, Geisinger - has reported the following disclosures: TG Therapeutics [Consultant/Advisor]

Luis Midence, PharmD, Staff Member, Geisinger - has nothing to disclose. 

Kenneth McCall, PharmD, FAPhA, Staff Member, Binghamton University School of Pharmacy & Pharmaceutical Sciences - has nothing to disclose. 

Moderator(s): 

Daniel Longyhore, PharmD, EdD, BCACP, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe emerging trends surrounding national GLP-1 usage.
• Illustrate strategies employed by Enterprise Pharmacy Institute to promote optimal utilization. 
• Explain the regulatory and clinical context surrounding the use of compounded GLP-1 receptor agonists (GLP-1 RAs).
• Compare adverse event profiles between compounded and non-compounded GLP-1 RAs using FAERS data.
• Identify the most common medication errors associated with compounded GLP-1 RA therapies found in FAERS reports and their potential consequences.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Daniel Longyhore, PharmD, EdD, BCACP; Eric Wright, PharmD, MPH; Melissa Kern, MPH and Lisabeth Karetsky, CPhT have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Gale Shalongo, DNP, MSN, RN, ACNS, BC, Kelly Ryan Shaw, PsyD, Sara Gaines, PharmD, and Angela Slampak-Cindric, PharmD, BCPS

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None